Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Raised by Vest Financial LLC

Vest Financial LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,989 shares of the biopharmaceutical company’s stock after buying an additional 762 shares during the quarter. Vest Financial LLC’s holdings in Gilead Sciences were worth $553,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in GILD. NatWest Group plc bought a new position in Gilead Sciences during the fourth quarter valued at about $6,808,000. Golden State Wealth Management LLC acquired a new stake in Gilead Sciences in the 4th quarter worth approximately $70,000. Beese Fulmer Investment Management Inc. bought a new stake in Gilead Sciences during the fourth quarter worth approximately $213,000. Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in Gilead Sciences by 4.8% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 159,693 shares of the biopharmaceutical company’s stock valued at $14,751,000 after purchasing an additional 7,295 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in shares of Gilead Sciences by 0.3% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,034,060 shares of the biopharmaceutical company’s stock valued at $280,256,000 after purchasing an additional 10,076 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD stock opened at $96.04 on Monday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $100.51. The stock has a market capitalization of $119.69 billion, a PE ratio of 1,067.11, a PEG ratio of 1.25 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock’s fifty day moving average is $93.04 and its 200-day moving average is $86.76.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter last year, the company posted $2.29 EPS. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. Equities research analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GILD has been the topic of a number of research analyst reports. Citigroup initiated coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price on the stock. Robert W. Baird raised their price target on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their target price for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Mizuho raised their target price on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Finally, Barclays increased their price objective on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.39.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock valued at $53,611,715 over the last quarter. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.